Cisplatin‐resistance induces lung squamous carcinoma cell growth by nicotine‐mediated α7nAchR/HDAC1/Cyclin D1/pRb cell cycle activation
Cell Biochemistry and Function · 2024
DOI: 10.1002/cbf.3990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Function, 2024. Verfasst von Leh Rao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, Shaoguan University, Shaoguan City, Guangdong Province, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sichuan University, Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
The majority of adenocarcinoma lung cancer is found in nonsmokers. A history of tobacco use is more common in squamous cell carcinoma of the lung. The aim of this study is to identify the cisplatin (CDDP)‐resistance that promotes lung squamous carcinoma cell growth through nicotine‐mediated HDAC1/7nAchR/E2F/pRb cell cycle activation. Squamous cell carcinoma (NCI‐H520 and NCI‐H157) cells were examined after cisplatin and nicotine treatment by 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl‐2H‐tetrazolium bromide assay, cell migration assay, immunofluorescence staining, western blot analysis, and immunoprecipitation analysis. Consequently, CDDP is released from DNA and Rb phosphorylated pRb as a result of nicotine‐induced cancer cell proliferation through 7nAchR, which then triggers the opening of the HDAC1 cell cycle. The cell cycle is stopped when CDDP adducts are present. Nicotine exerts cancer cytoprotective effects by allowing HDAC1 repair mechanisms to re‐establish E2F promoting DNA stimulation cell cycle integrity in the cytosol and preventing potential CDDP and HDAC1 suppressed in the nuclear. Concentration expression of nicotine causes squamous carcinoma cell carcinogens to emerge from inflammation. COX2, NF‐KB, and NOS2 increase as a result of nicotine‐induced squamous carcinoma cell inflammation. Nicotine enhanced the cell growth‐related proteins such as α7nAchR, EGFR, HDAC1, Cyclin D, Cyclin E, E2F, Rb, and pRb by western blot analysis. It also induced cancer cell inflammation and growth. As a result, we suggest that nicotine will increase the therapeutic resistance effects of CDDP. This has the potential to interact with nicotine through α7nAchR receptors and HDAC1/Cyclin D/E2F/pRb potentially resulting in CDDP therapy resistance, as well as cell cycle‐induced cancer cell growth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Technology, Shaoguan University, Shaoguan City, Guangdong Province, People's Republic of China.
- Department of Biomedicine, Chengdu Medical College, Chengdu, People's Republic of China.
Förderung
- Sichuan University
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Rao, L., Guo, D., & Wu, J. P. (2024). Cisplatin‐resistance induces lung squamous carcinoma cell growth by nicotine‐mediated α7nAchR/HDAC1/Cyclin D1/pRb cell cycle activation. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.3990
Vancouver
Rao L, Guo D, Wu JP. Cisplatin‐resistance induces lung squamous carcinoma cell growth by nicotine‐mediated α7nAchR/HDAC1/Cyclin D1/pRb cell cycle activation. Cell Biochemistry and Function. 2024. doi:10.1002/cbf.3990
BibTeX
@article{Rao2024,
author = {Rao, Leh and Guo, Dan and Wu, Jia-Ping},
title = {Cisplatin‐resistance induces lung squamous carcinoma cell growth by nicotine‐mediated α7nAchR/HDAC1/Cyclin D1/pRb cell cycle activation},
journal = {Cell Biochemistry and Function},
year = {2024},
doi = {10.1002/cbf.3990}
}
EUVIMED